Proteomic analysis of liver cancer cells treated with 5-Aza-2′-deoxycytidine (AZA)
✍ Scribed by Shujun Bai; Aiping Tong; Quek Choon Lau; Rui Liu; Minghai Tang; Lijuan Chen; Canhua Huang
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 312 KB
- Volume
- 70
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract In gastric cancer, increasing numbers of genes have been reported to be silenced by aberrant methylation. However, global analysis of epigenetic inactivation in cancer cells has rarely been performed. For screening the genes upregulated by the demethylating agent 5‐aza‐2′‐deoxycytidine
## Abstract ## BACKGROUND General and site‐specific DNA methylation is associated with tumor progression and resistance in several cancers, including chronic myelogenous leukemia (CML). Decitabine is a hypomethylating agent that has shown encouraging preliminary anti‐CML activity. This study evalu
## Abstract The __in vitro__ and __in vivo__ antineoplastic activity of 5‐AZA‐2'‐deoxycytidine (5‐AZA‐CdR) and β‐2‐deoxythioguanosine (TGdR) on L1210 an L1210/ARA‐C (resistant to cytosine arabinoside) leukemic cells was investigated. 5‐AZA‐CdR was a very potent cytotoxic agent against the L1210 leu